MGK_2 a shout out to you for your informative posts that frankly inspire investors when it's kind of needed.

I have a question: Sepsis. 1.7 reported cases reported annually. Fully one third of these patients die as a result of sepsis. Current treatment appears hit and miss. I note that sepsis appears on ohms list of potential target diseases for leronlimab. I know we are knee-deep in trials at the present, but your thoughts on looking at sepsis for a trial. Seems it might take little time and it's a target rich environment. Low hanging fruit?